| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net earnings/(loss) | 5,970 | 3,775 | 2,462 | -9,009 |
| Depreciation and amortization, net | 3,034 | 2,023 | 1,012 | 7,720 |
| Deferred income taxes | -573 | -214 | 223 | -1,298 |
| Stock-based compensation | 420 | 281 | 144 | 387 |
| Impairment charges | 514 | 318 | - | 1,010 |
| Divestiture gains and royalties | 880 | 585 | 292 | 838 |
| Acquired iprd | 2,328 | 1,695 | 188 | 13,343 |
| Equity investment (gains)/losses, net | 90 | -100 | -78 | - |
| Equity investment (gains)/losses | - | - | - | 221 |
| Contingent consideration fair value adjustments | 336 | 336 | - | - |
| Other adjustments | 76 | 2 | -10 | -123 |
| Receivables | 314 | 469 | -15 | -121 |
| Inventories | 255 | 165 | 169 | 661 |
| Accounts payable | 88 | -72 | -85 | -333 |
| Rebates and discounts | 1,957 | 254 | -627 | 1,889 |
| Income taxes payable | 320 | -567 | 54 | -1,381 |
| Other | 597 | 837 | 1,059 | 101 |
| Net cash provided by/(used in) operating activities | 12,182 | 5,871 | 1,954 | 10,751 |
| Sale and maturities of marketable debt securities | 1,573 | 744 | 220 | 1,060 |
| Purchase of marketable debt securities | 1,922 | 1,257 | 636 | 398 |
| Proceeds from sales of equity investments | 61 | 12 | 12 | 60 |
| Capital expenditures | 941 | 621 | 260 | 870 |
| Divestiture and other proceeds | 792 | 513 | 243 | 766 |
| Acquisition and other payments, net of cash acquired | 2,237 | 363 | 78 | 21,774 |
| Net cash provided by/(used in) investing activities | -2,674 | -972 | -499 | -21,156 |
| Proceeds from issuance of short-term debt obligations | 0 | 0 | 0 | 2,987 |
| Repayments of short-term debt obligations | 0 | 0 | - | 3,000 |
| Other short-term financing obligations, net | 431 | 426 | 368 | 504 |
| Proceeds from issuance of long-term debt | 0 | 0 | 0 | 12,883 |
| Repayments of long-term debt | 872 | 643 | - | 2,873 |
| Repurchase of common stock | - | - | - | 0 |
| Dividends | 3,783 | 2,520 | 1,258 | 3,645 |
| Stock option proceeds and other, net | -95 | -92 | -103 | -87 |
| Net cash provided by/(used in) financing activities | -4,319 | -2,829 | -993 | 6,769 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | 190 | 194 | 66 | 10 |
| Increase/(decrease) in cash, cash equivalents and restricted cash | 5,379 | 2,264 | 528 | -3,626 |
| Cash and cash equivalents at beginning of period | 10,347 | 10,347 | 10,347 | 11,519 |
| Cash and cash equivalents at end of period | 15,726 | 12,611 | 10,875 | 7,893 |
BRISTOL MYERS SQUIBB CO (BMYMP)
BRISTOL MYERS SQUIBB CO (BMYMP)